Biotech company Biogen (NASDAQ: BIIB) announced better-than-expected revenue in Q3 CY2025, with sales up 2.8% year on year to $2.53 billion. Its non-GAAP profit of $4.81 per share was 23.9% above analysts’ consensus estimates.

Is now the time to buy BIIB? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Biogen’s third quarter results came in ahead of Wall Street’s revenue and profit expectations, driven by robust performance from recently launched products and continued strength in its multiple sclerosis portfolio. Management attributed much of the growth to LEQEMBI, SKYCLARYS, and ZURZUVAE, which together posted significant year-on-year gains. CEO Christopher Viehbacher highlighted that “launch products again in this quarter, and if I look at this year-to-date as well, more than have offset the MS decline on a year-to-date basis.” Despite generic pressures in Europe, particularly for the MS franchise, the company’s ability to grow new products and maintain cost discipline supported an improved operating margin.

Looking forward, Biogen’s updated guidance reflects both optimism around the expansion of its late-stage pipeline and caution about near-term profitability. Management lowered full-year adjusted EPS guidance, noting planned investments in business development, prelaunch activities, and pipeline expansion as key factors. CFO Robin Kramer explained, “We have updated our non-GAAP EPS guidance to reflect a stronger underlying business outlook and investment for growth from business development transactions expected to close in the fourth quarter.” The company is prioritizing geographic expansion for SKYCLARYS and LEQEMBI, further development of early-stage assets, and continued cost management as it prepares for multiple upcoming late-stage clinical readouts.

Key Insights from Management’s Remarks

Management credited the quarter’s positive results to strong demand for new launch products, resilience in the U.S. multiple sclerosis business, and ongoing pipeline development, while noting ongoing investments to support future launches and product access.

• Launch product momentum: LEQEMBI, SKYCLARYS, and ZURZUVAE drove year-over-year growth, with LEQEMBI showing global demand strength and ZURZUVAE expanding provider uptake for postpartum depression. SKYCLARYS is now available in 34 markets, supporting international growth.
• MS franchise resilience: U.S. multiple sclerosis revenue benefitted from strategic support for VUMERITY and favorable inventory adjustments, while European sales faced accelerated generic competition, particularly for TECFIDERA.
• Pipeline expansion: Biogen’s late-stage pipeline now includes 10 Phase III or Phase III-ready programs across diverse indications, including lupus, nephrology, and rare diseases. Management emphasized accelerating enrollment for key studies, such as litifilimab in lupus.
• Operational efficiency: The company maintained flat operating expenses year-on-year despite new product launches and R&D investments, attributing this to disciplined cost management and the ongoing Fit-for-Growth initiative.
• Business development activity: Biogen announced agreements to acquire Alcyone Therapeutics and license a C5aR1 antagonist from Vanqua Bio, aiming to strengthen its early-stage pipeline and broaden its immunology portfolio.

Drivers of Future Performance

Biogen’s outlook is shaped by continued investment in new product launches, pipeline advancement, and expected headwinds in certain mature markets.

• Accelerating pipeline investments: Management plans to increase spending on new clinical studies, prelaunch activities, and direct-to-consumer advertising for launch products, which will impact margins in the short term but is expected to support medium-term growth.
• Geographic and market expansion: The company is targeting expanded reimbursement and commercial launches for products like SKYCLARYS and LEQEMBI in additional international markets, with a particular focus on securing broader access and physician adoption.
• MS franchise challenges: Biogen expects increased generic competition for TECFIDERA in Europe to accelerate, creating revenue headwinds while it works to offset these through growth in other portfolio areas and operational efficiencies.

Catalysts in Upcoming Quarters

Looking ahead, the StockStory team will be monitoring (1) the pace of commercial adoption for LEQEMBI’s subcutaneous and at-home formulations, (2) progress on reimbursement and geographic expansion for SKYCLARYS and other launches, and (3) advancement of key Phase III pipeline programs, including litifilimab and BIIB080. Execution on cost management and the impact of generic pressures in Europe will also be important to track.

Biogen currently trades at $151.38, up from $148.19 just before the earnings. At this price, is it a buy or sell? The answer lies in our full research report (it’s free for active Edge members).

Now Could Be The Perfect Time To Invest In These Stocks

When Trump unveiled his aggressive tariff plan in April 2025, markets tanked as investors feared a full-blown trade war. But those who panicked and sold missed the subsequent rebound that’s already erased most losses.

Don’t let fear keep you from great opportunities and take a look at Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.